Overview

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

Status:
Completed
Trial end date:
2017-01-05
Target enrollment:
Participant gender:
Summary
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.
Phase:
Phase 3
Details
Lead Sponsor:
Foresee Pharmaceuticals Co., Ltd.
Collaborator:
QPS-Qualitix
Treatments:
Leuprolide